Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Aripiprazole in the treatment of the psychosisprodrome: An open-label pilot study
Ist Teil von
British journal of psychiatry, 2007-12, Vol.191 (S51), p.s96-s101
Ort / Verlag
London: Cambridge University Press
Erscheinungsjahr
2007
Quelle
Free E-Journal (出版社公開部分のみ)
Beschreibungen/Notizen
BackgroundResearch studies for the treatment of the putative prodromal phase ofpsychotic disorders have begun to appearAimsTo obtain preliminary evidence of the short-term efficacy and safety ofaripiprazole treatment in people with the psychosis prodromeMethodFifteen participants meeting prodrome criteria (mean age 17.1 years,s.d.=5.5) enrolled in an open-label, single-site trial withfixed-flexible dosing of aripiprazole (5–30 mg/day) for 8 weeksResultsIn the mixed-effects repeated-measures analysis, improvement frombaseline on the Scale of Prodromal Symptoms total score was statisticallysignificant by the first week. No participant converted to psychosis and13 completed treatment. Neuropsychological measures showed no consistentimprovement; mean weight gain was 1.2 kg. Akathisia emerged in 8participants, but the mean Barnes Akathisia Scale score fell to baselinelevels by the final visit. Adverse events were otherwise minimalConclusionsAripiprazole shows a promising efficacy and safety profile for thepsychosis prodrome. Placebo-controlled studies are indicated